Table 1.
Clinical and epidemiological characteristics of study populations.
| Patient Code | Region of Origin | Sexa | Ageb (years) | Length of HIV diagnosis (years) | Length of Follow-upc (years) | HIV-RNA load (copies/mL) Median [IQR] |
Nº of HIV-RNA blipsd | CD4 count (cells/µL) Median [IQR]e |
|---|---|---|---|---|---|---|---|---|
| EC-1 | Europe | F | 31 | 24 | 13.48 | < 50 | 0 | 941 [887 - 1026] |
| EC-2 | Europe | F | 35 | 4 | 2.88 | < 50 | 2 | 1125 [1032 - 1176] |
| EC-3 | Europe | F | 40 | 20 | 11.88 | < 50 | 4 | 987 [944 - 1099] |
| EC-4 | Europe | M | 43 | 12 | 9.88 | < 50 | 3 | 830 [563 - 946] |
| EC-5 | Europe | F | 22 | 14 | 12.56 | < 50 | 5 | 725 [658 - 824] |
| EC-6 | Europe | F | 32 | 24 | 12.88 | < 50 | 0 | 945 [851 - 1050] |
| EC-7 | Europe | M | 33 | 15 | 11.80 | < 50 | 0 | 804 [770 - 837] |
| EC-8 | Europe | F | 24 | 18 | 12.48 | < 50 | 1 | 1171 [1016 - 1342] |
| EC-9 | Europe | F | 46 | 13 | 1.64 | < 50 | 0 | 1386 [1139 - 1604] |
| EC-10 | Europe | F | 26 | 20 | 12.00 | < 50 | 3 | 733 [329 - 774] |
| EC-11 | Europe | F | 36 | 20 | 12.80 | < 50 | 1 | 1109 [874 - 1213] |
| EC-12 | Europe | F | 32 | 23 | 9.24 | < 50 | 2 | 956 [855 - 1125] |
| EC-13 | Europe | M | 21 | 14 | 10.64 | < 50 | 1 | 555 [458 - 637] |
| EC-14 | Europe | M | 28 | 18 | 13.24 | < 50 | 2 | 516 [472 - 574] |
| EC-15 | Europe | F | 40 | 18 | 12.48 | < 50 | 5 | 776 [697 - 943] |
| EC-16 | Europe | F | 38 | 25 | 12.24 | < 50 | 1 | 801 [700 - 885] |
| EC-17 | ND | M | 37 | 23 | 12.56 | < 50 | 2 | 676 [541 - 960] |
| EC-18 | LA | F | 24 | 6 | 4.88 | < 50 | 0 | 1290 [1122 - 1388] |
| EC-19 | Europe | M | 46 | 5 | 4.08 | < 50 | 2 | 626 [351 - 885] |
| EC-20 | Europe | M | 42 | 16 | 5.56 | < 50 | 0 | 716 [613 - 887] |
| EC-21 | Europe | F | 42 | 11 | 12.16 | < 50 | 0 | 480 [407 - 578] |
| EC-22 | LA | F | 27 | 17 | 10.88 | < 50 | 1 | 872 [766 - 1113] |
| EC-23 | Europe | M | 41 | 21 | 11.40 | < 50 | 0 | 859 [675 - 950] |
| EC-24 | Europe | M | 43 | 21 | 6.72 | < 50 | 1 | 674 [503 - 828] |
| EC-25 | Europe | M | 34 | 24 | 11.88 | < 50 | 4 | 523 [482 - 644] |
| EC-26 | Europe | M | 30 | 22 | 11.48 | < 50 | 3 | 720 [636 - 958] |
| EC-27 | Europe | M | 35 | 21 | 9.88 | < 50 | 1 | 989 [939 - 1149] |
| EC-28 | Europe | F | 34 | 17 | 12.40 | < 50 | 1 | 792 [666 - 967] |
| EC-29 | LA | F | 32 | 6 | 4.72 | < 50 | 0 | 1463 [1406 - 1865] |
| EC-30 | ND | M | 34 | 8 | 5.24 | < 50 | 2 | 762 [560 - 1050] |
| NC-3 | Europe | M | 22 | 1.78 | 1.78 | 211622 [60738 - 395936] | NA | 380 [330 - 519] |
| NC-4 | Europe | M | 26 | 2.49 | 2.49 | 26824 [17064 - 74553] | NA | 707 [537 - 762] |
| NC-5 | Europe | M | 37 | 2.24 | 2.24 | 115556 [67095 - 164576] | NA | 413 [315 - 460] |
| NC-6 | Europe | M | 42 | 3.10 | 3.10 | 74579 [23460 - 129395] | NA | 379 [307 - 651] |
| NC-7 | Europe | M | 54 | 1.63 | 1.63 | 94607 [53113 - 144196] | NA | 535 [341 - 847] |
| NC-8 | Europe | M | 25 | 1.30 | 1.30 | 24760 | NA | 338 [290 -349] |
| NC-9 | Europe | M | 35 | 1.84 | 1.84 | 9692 [6705 - 12153] | NA | 936 [767 - 1064] |
| NC-11 | Europe | M | 52 | 2.89 | 2.89 | 8413 [6901 - 11876] | NA | 530 [480 - 689] |
| NC-14 | Europe | M | 31 | 3.50 | 3.50 | 17799 [9583 - 23499] | NA | 579 [470 - 660] |
| NC-15 | Europe | M | 25 | 3.26 | 3.26 | 15849 [14219 - 71265] | NA | 446 [399 - 573] |
| NC-16 | Europe | F | 49 | 20.64 | 20.64 | 19300 [11600 - 27100] | NA | 634 [537 - 878] |
EC, elite controller; NC, non-controller; ND, no data; NA, not applicable; LA, Latin America; aF, Female and M, Male; bAge at inclusion as EC or NC; cLength of follow-up maintaining EC or NC status; dAll elite controller subjects maintained undetectable HIV RNA load, but some of them experienced a few blips throughout the follow-up; eMedian [interquartile range] of all CD4 counts available during the follow-up period.